$1.34▼ 0.01 (0.74%)
Real-time prices · US MarketsHealthy balance sheet and financial position.
currently unprofitable (-82% margin).
Quality
2
Health
6.7
Growth
4.7
Valuation
6.3
Sentiment
5.2
Analyst Target
$2.16
▲ +61.0% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-3.3×
next 12 months est.
Market Cap
$417M
market capitalization
Div Yield
—
dividend yield
Profit Margin
-82.5%
net profit margin
Gross Margin
29.4%
revenue minus COGS
ROE
-929.3%
return on equity
Beta
2.31
vs S&P 500
52-Week Range
$1 — $3
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Pacific Biosciences of Californ right now?
Pacific Biosciences of Californ's Q·Score is 4.8/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Healthy balance sheet and financial position. Key area to monitor: currently unprofitable (-82% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for PACB?
The consensus price target for PACB is $2.16, based on ratings from 7 Wall Street analysts. This is 61.0% above the current price of $1.34. Price targets are forward-looking estimates and not guarantees of future performance.
Is PACB overvalued or undervalued?
Pacific Biosciences of Californ (PACB) scores in line with sector averages on valuation metrics. The consensus analyst price target of $2.16 is 61% above the current price.
When does Pacific Biosciences of Californ report its next earnings?
Pacific Biosciences of Californ's next earnings report is expected on approximately November 5, 2026.
What is Pacific Biosciences of Californ's profit margin?
Pacific Biosciences of Californ has a net profit margin of -82.5%, indicating the company is currently operating at a net loss. Its gross margin stands at 29.4%, reflecting a more cost-intensive business model.
Is Pacific Biosciences of Californ's revenue growing?
Pacific Biosciences of Californ is reporting revenue declining 1.9% year-over-year.